SLC5A2 and liver dysplastic nodule: Although new hypoglycemic drugs with additional mechanisms are being tested for DN, such as SGLT2 inhibitor and GLP-1 activator (Warren et al., 2019), drugs targeting at renal fibrosis are needed to be used as adjuvant treatments to prevent the development and progression of DN.